ArticleNew microbes and new infections2026
Seroprevalence and risk factors of Hepatitis A virus among Palestinian refugees in North Lebanon: A pilot study to inform vaccination and public health policy.
Article in New microbes and new infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis A virus (HAV) is a vaccine-preventable cause of acute viral hepatitis, transmitted primarily via the fecal-oral route and occasionally leading to severe complications. While Lebanon has experienced major HAV outbreaks in recent years, data on Palestinian refugees remain limited. This study aimed to determine HAV seroprevalence, identify associated risk factors, and assess the potential healthcare burden within this vulnerable population in North Lebanon. Methods: A cross-sectional study was conducted from December 2023 to May 2024, involving 84 systematically selected Palestinian refugees attending Safad Hospital in Al-Baddawi camp, North Lebanon. Socio-demographic and clinical data were collected using standardized questionnaire, and serum samples were tested for IgM and total anti-HAV antibodies. Results: Overall, 78.6% of participants were seropositive for total anti-HAV antibodies, reflecting accumulated immunity resulting from prior vaccination and/or past natural infection, while 2.4% tested positive for IgM anti-HAV, indicating limited evidence of recent or acute infection at the time of the survey. Multivariable analysis showed that individuals aged 16-30 years were at higher risk of HAV seropositivity ( Conclusions: These findings highlight the continued presence of susceptible individuals, particularly in younger age groups, and support the need for sustained vaccination efforts, improved surveillance, and targeted public health interventions in refugee settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.